Figure 7. Therapeutic efficacy of the compound T6167923 in mice.

BALB/c mice (n = 6/per group) were injected (i. p.) with different amounts of compounds (0.17 mg, or 1 mg), 30 min later injected with 1 μg of SEB (equivalent to 2LD₅₀) followed by LPS (90 μg, sub lethal dose) 2 h later. Mice were observed to determine if mice survived, or time of death. Control mice injected only with 90 μg of LPS or 1 μg of SEB survived. (a) Survivability of mice with pre-treatment of the compound T6167923 (P-values from log-rank test ≤0.0149 and ≤0.0001 of treated group T6167923 (0.17 mg) +SEB+LPS and T6167923 (1 mg) +SEB+LPS, respectively, comparing with untreated group SEB (1.0 μg) + LPS ;(b) Survivability of mice with pretreatment of the compound T5996207. (P-values from log-rank test ≤ 0.4592 and ≤0.0001 of treated group T5996207 (0.17 mg) +SEB+LPS and T6167923 (1 mg) +SEB+LPS, respectively, comparing with untreated group SEB (1.0 μg) +LPS. Data represent three separate experiments.